Abstracts by keywords: discount contracts
The development in health care includes the implementation of contracts between different players as one of the main regulating factors. Contracts don't run by themselves; it's not enough to agree on content and sign it. The evaluation must be taken into account and planned as early as when the contract is concluded, and not only after 3 years, but continuously and concomitantly. The appropriate source for the information, as well as the type and amount of information required, depends on the type of contract and the content of the contract. In order to consider selective contracts with doctors or groups, data and evaluations from random samples of relevant size, which also allow regionally valid considerations and extrapolations, are required. Evaluations from billing data are not sufficient here because they do not adequately reflect medical behavior.
23.09.2012
Since the legislator activated the option of drug discount contracts in the GKV Competition Strengthening Act (April 2007), corresponding discount contracts in the generic market segment have developed into a successful model. On the other hand, the objections repeatedly raised by interested parties, in particular pharmaceutical companies, with regard to patient compliance or alleged market share losses of pharmaceutical SMEs, stand up to neither public opinion nor empirical scrutiny. Discount agreements form an efficient and forward-looking competitive instrument between statutory health insurance companies and the pharmaceutical industry.
17.10.2010
The past and presumably also the current reforms of politics in the pharmaceutical sector strengthen the service providers working in the field of discount agreements according to §130a SGB V for the GKV. The reason for this lies essentially in the complexity of the materials as well as in the bundling of demand volumes. Despite the merger of several health insurance companies, however, they wish to see their individual interests reflected in the contract. Service providers like GWQ ServicePlus AG are measured by whether they enable individual contract strategies in the pharmaceuticals sector on the one hand and whether they successfully achieve high discounts on the other. This is accompanied by the complex task of the technical implementation of the contracts and also a far-reaching consulting service on drug contracts. This concerns pharmaceutical, procurement law, data technology and financial aspects.